Profile of Insulin Resistance of Pregnant Women at Late Third Trimester in Nigeria: A Descriptive Cross-Sectional Report

JO Chionuma, IJ Akinola¹, AO Dada², PO Ubuane³, TO Kuku-Kuye, FD Olalere

Departments of Obstetrics and Gynaecology, ¹Paediatrics and ²Pathology, Lagos State University College of Medicine/Lagos State University Teaching Hospital, Ikeja, Lagos, ³Department of Paediatrics, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria

 Received:

 01-Apr-2022;

 Revision:

 07-Jul-2022;

 Accepted:

 23-Jul-2022;

 Published:

 26-Oct-2022

INTRODUCTION

1736

2 Insulin regulates the homeostasis of blood glucose in the body. Insulin resistance (IR) has been defined as the decrease in the biological action of insulin that mainly presents as high blood levels of glucose. ^[1-5] Pregnancy is associated with decrease sensitivity to insulin as it advances due to the antagonistic effects of pregnancy hormones, among other factors which increase as pregnancy progresses.^[3-5] This pregnancy-associated IR is associated with higher risk of caesarean section, gestational hypertension, and preterm births.^[6,7] Moreover, the offspring of mothers with IR are far more likely to develop metabolic syndrome, obesity or type II diabetes.^[8-12] Thus, early detection of IR in pregnant women followed by appropriate interventions may limit these adverse effects.

Access this article online					
Quick Response Code:	Website: www.njcponline.com				
	DOI: 10.4103/njcp.njcp_233_22				

Background: Exaggerated level of insulin resistance (IR) is associated with poor pregnancy outcomes. Identifying affected women may forestall these outcomes. There are few reports on IR and its predictors among pregnant women in Nigeria. Aim: To determine the profile of IR, using the homeostatic model assessment of insulin resistance (HOMA-IR), and its predictors among parturient Nigerian women in third trimester. Patients and Methods: A cross-sectional baseline data of healthy pregnant women in third trimester, consecutively recruited into a cohort study that evaluated IR and neonatal outcomes at a tertiary maternity. Sociodemographic and clinical data were obtained. Fasting venous blood was analyzed for glucose and insulin and HOMA-IR was calculated. **Results:** We consecutively recruited 401 healthy pregnant women between 28 and 41 weeks [means \pm SD = 37.4 \pm 0.8 weeks]; mean age 31.52 \pm 4.3 years (range: 20-41 years). Median (IQR) HOMA-IR was 1.15 (0.63, 1.96; range: 0.02-11.73). Binary multivariable logistic regression showed overweight- [aOR (95% CI = 3.29 (1.18, 9.13)], hyperglycemia- [aOR (95% CI) = 2.98 (1.19, 6.90)], and hypertension as independent predictors of IR [aOR (95% CI) = 2.85 (1.18, 6.90)]. Conclusion: Among nondiabetic Nigerian pregnant women in late third trimester, IR was independently associated with overweight, hypertension, and hyperglycemia. Control of adiposity is a potential target for control of IR and consequently its outcomes.

KEYWORDS: Gestational diabetes, HOMA-IR, maternal hyperinsulinemia, Nigerian

Homeostatic model assessment of insulin resistance (HOMA-IR) is a simple, cheap, and indirect means of estimating IR.^[13] It has the advantage of a single sampling compared with oral glucose tolerance test which requires multiple sampling. Previous researchers have documented conflicting reports on changes in IR (measured with HOMA-IR) in pregnancy; while some authors observed increasing IR as pregnancy advanced others did not.^[14,15] Identification of factors

Address for correspondence: Dr. JO Chionuma, Lecturer/Honorary Consultant Obstetrician and Gynaecologist, Department of Obstetrics and Gynaecology, Lagos State University College of Medicine/Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria. E-mail: joy.agbara@lasucom.edu.ng

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Chionuma JO, Akinola IJ, Dada AO, Ubuane PO, Kuku-Kuye TO, Olalere FD. Profile of insulin resistance of pregnant women at late third trimester in Nigeria: A descriptive cross-sectional report. Niger J Clin Pract 2022;25:1736-44.

associated with IR among pregnant women may serve as potential targets for preventive interventions such as dietary and lifestyle modification to forestall negative maternal–neonatal outcomes. In Nigeria, there are few studies on IR among pregnant women. Imoh *et al.*^[16] and Imoh & Ocheke^{[17],} respectively identified overweight and family history of DM as predictors of IR in early third-trimester pregnant women in North-Central Nigeria. However, their findings may not extrapolate to other parts of the country because of variations in factors such as dietary practices, activity level, and prevalence of obesity. This study was thus aimed at determining the profile of IR and its predictors in parturient Nigerian women in the third trimester in Lagos, Nigeria.

METHODOLOGY

Study design and location

The current report is the cross-sectional descriptive baseline data of pregnant women recruited at third-trimester into a prospective cohort study aimed at determining the association between maternal IR and neonatal outcomes. The study was carried out in the clinics and lying-in wards of a tertiary centre in South-west Nigeria.

Study population and sampling technique

We consecutively recruited pregnant women with singleton pregnancies from the ante-natal clinics. We excluded those with established or suspected prepregnancy or chronic diabetes, chronic hypertensive disorders, chronic medical illnesses, congenitally abnormal pregnancy and any acute illness or those on hypoglycemic medications. However, we did not exclude those found to have elevated blood pressure at recruitment.

Sample size

The minimum sample size was determined using the standard formula for proportions: $n = z^2/p$ q/d^2 , where n = desired sample size; z = the fraction of the area under the normal distribution curve covered by two standard deviations on either side of normal distribution which is equal to 1.96 in a two-tailed test; P = estimated or known prevalence of the condition—a value of 50% (0.5) was used as the prevalence of IR measured by HOMA-IR, q = 1 - p; d = tolerable margin of error (80%). The calculated sample size was 384.16 which was rounded up to 400.

Ethical considerations

Ethical approval (LREC/06/10/1323) was sought and obtained before commencement. Written informed consent was also obtained from the pregnant women prior to enrolment.

Data collection

Trained research assistants used a structured data collection form to obtain the following data from eligible women and their medical records: maternal and paternal sociodemographic characteristics (age, sex, occupation, education), anthropometric (weight, height), and clinical data (family history of diabetes). Maternal body mass index (BMI) was computed as weight (kg)/Height (m²).

Specimen collection and preparation

Participants were bled in the morning following an 8 to 10 hours overnight fast. With the participant sitting in a comfortable position, antiseptic preparation of the antecubital region was done using methylated spirit swabs and a tourniquet applied proximal to the antecubital vein. With gloved hands, about 5 mm of venous blood was collected into vacutainer tubes using a multiple sampling needle. Three mm of venous blood was collected into plain vacutainer tubes, while 2 mm of venous blood was collected into fluoride oxalate vacutainer tubes. The samples in the plain tubes were allowed to stand for 30 min and subsequently centrifuged at 3,000 rpm for 5 min and the supernatant (serum) separated and stored at -80°C till the time of analysis; similarly, the blood samples in fluoride oxalate bottles were centrifuged at 3,000 rpm for 5 min and the supernatant (plasma) separated and stored at -80°C pending analysis. The multiple sampling needles were discarded into sharps boxes and the infranatant from the separated blood specimen were disposed through the Hospital Environmental Safety Department. Hemolyzed, icteric, and lipemic samples were excluded and repeated thawing and freezing was avoided. Analysis of specimen was carried out in the Chemical Pathology Laboratory, Department of Pathology, Lagos State University College of Medicine, Ikeja Lagos Nigeria. Laboratory analysis was done in batches and within, between and day to day precision was determined using quality control sera.

Serum insulin was analyzed using enzyme-linked immunosorbent assay (ELISA) kit for quantitative determination of insulin levels in Human serum. The principle of the assay is based on antigen antibody reaction. The results were read using a microplate reader.

Serum glucose

Glucose is oxidized by glucose oxidase to gluconic acid and hydrogen peroxide which in conjunction with peroxidase reacts with chloro-4-phenol and 4-amino-antipyrine to form a red quinonimine. The absorbance of the colored complex proportional to the concentration of glucose in the sample was measured at 500 nm.

Insulin resistance estimation

HOMA-IR was calculated as fasting insulin (μ U/mL) $_{\times}$ fasting plasma glucose (mmol/L)/22.5.

Operational definitions

We defined hyperglycemia in pregnancy as fasting serum glucose >91.0 mg/dL^[18]; hyperinsulinemia fasting serum insulin (FSI) more as than 20.0 $\mu U/Ml^{[19]}$ and IR as HOMA-IR values more than the 75th percentile of the HOMA-IR values of our sample population (HOMA-IR >1.96).^[20,21] In the absence of data on the women's pre-pregnancy weight or BMI (to determine true pre-pregnancy adiposity), we used the absolute weight and BMI at recruitment as surrogates; according to Imoh & Ocheke,^[17] a third-trimester weight of \geq 95 kg is associated with higher IR in Nigerian pregnant women in third trimester. We thus categorized weight into overweight (≥95.0 kg) and normal-weight (<95.0 kg). This value corresponded to 94th percentile of the weight distribution of our sample. The corresponding 94th percentile BMI was 36.4; hence we defined higher adiposity as \geq 36.5 and lower adiposity as <36.5.

Data management and analysis

We extracted data from data collection forms into Microsoft Excel Worksheet 2010 for data cleaning, then imported into R for analysis (using JASP version 0.16, a free open-source graphical user interphase; University of Amsterdam, Netherlands; https://jasp-stats.org/download/). After checking for outliers, implausible values, and distribution (Shapiro-Wilk test), we summarized categorical variables with frequencies and percentages and continuous variables with means \pm standard deviation (SD) or medians [interquartile range (IQR)] and percentiles. Outliers were assessed for possible errors while significantly skewed variables were log-transformed and then back-transformed. Mann-Whitney U test was used to compare continuous variables (HOMA-IR) between two groups. Two-by-two contingency tables with Fisher's exact test was used to compare IR and categorical variables. Spearman's correlation coefficient rho (ρ) was used to determine linear association between HOMA-IR and continuous variables and scatter-plots with the line of locally estimated scatterplot smoothing (LOESS) to visually assess these relationships. Potential predictors with significant bi-variable association with HOMA-IR or IR were entered into multivariable linear or binary logistic regression models, respectively, to determine the independent predictors of IR. Probability (P) value of <0.05 was taken as statistically significant and effect sizes estimated with unadjusted and adjusted odds ratios (OR) at 95% confidence intervals (CI).

RESULTS

Overall, we recruited 401 pregnant women between 28 and 41 weeks gestational age [mean \pm SD = 37.4 \pm 0.8 weeks]. However, only two women were less than 37 weeks.

Socio-demographic, anthropometric and clinical characteristics

The means \pm SD (95% CI) age and gestational age (GA) were, respectively, 31.5 \pm 4.3 years (95% CI: 31.1, 31.9; range: 20.0–41.0) and 37.40.8 weeks (95% CI: 37.3, 37.4; Range: 28.0–41.0). More than four-fifths (83.8%) of the women had at least tertiary education and about two-thirds of them (63.5%) were of Yoruba ethnicity [Table 1]. Almost half of them were primiparous. The mean weight and BMI were 74.13 \pm 12.91 kg and 28.69 \pm 4.72 kg/m², respectively, suggesting that they were on average a "normal-weight," "low-BMI" population. Family history of DM was present in 10.6% (42/396) and 5.8% (23/396) had elevated blood pressure at recruitment.

Biochemical characteristics: Serum glucose, insulin and HOMA-IR of study participants

The proportion of women with hyperglycemia (fasting serum glucose \geq 92 mg/dL), hyperinsulinemia (fasting serum insulin >20.0 μ U/MI) and IR [HOMA-IR value greater than the 75th centile (>1.96)] were 5.29% (95% CI: 3.49, 7.95; N = 21/376), 6.06% (95% CI: 3.90, 8.90; N = 24/372), and 25.25% (95% CI: 21.23, 29.76; N = 100/396;), respectively. Table 2 shows the serum glucose, insulin, and HOMA-IR values



Figure 1: Scatterplots showing linear correlation between HOMA-IR and anthropometric variables. The blue curves show the line of *locally estimated scatterplot smoothing* (LOESS) showing the trend in HOMA-IR with increasing values of the independent variables (age, weight, height and BMI); the grey shaded areas show the confidence bands while the dots are data-points. Whereas HOMA-IR tended to be mostly flat for age and height, it showed a slight increase with weight from about 80 kg and BMI from about 34 kg/m² Abbreviations: ρ , Spearman's coefficient rho; CI, confidence interval; HOMA-IR, homeostatic model assessment of insulin resistance (a) HOMA-IR versus age, (b) HOMA-IR versus weight, (c)HOMA-IR versus height, (d) HOMA-IR versus BMI

1738

Table 1: Baseline socio-demographic and clinical characteristics of pregnant Nigerian women at late third trimester						
	n (%)	Mean±SD	95% CI of Mean (Upper, Lower)	Range		
Anthropometric						
Weight, kg	396	74.13±12.91	72.86, 75.41	47.00, 140.00		
Height, cm	395	160.69±6.58	160.04, 161.33	149.00, 175.00		
BMI, kg/m ²	395	28.69±4.72	28.23, 29.16	16.20, 50.20		
Educational level						
Primary	1 (0.3)					
Secondary	63 (15.9)					
Tertiary	314 (79.3)					
Postgrad	18 (4.5)					
Ethnic Group						
Yoruba	250 (63.5)					
Igbo	125 (31.7)					
Others	19 (4.8)					
Parity						
1	182 (46.3)					
2	124 (31.6)					
3	67 (17.0)					
4	18 (4.6)					
5	2 (0.5)					
Weight category*						
Overweight	27 (6.82)					
Normal-weight	369 (93.18)					
BMI category [†]						
High adiposity	24 (9.09)					
Low adiposity	360 (90.91)					

n, frequency; CI, confidence interval; GA, gestational age at enrolment; BMI, body-mass index in kg/m². * overweight was defined as weight at recruitment \geq 95.0kg and normal-weight as<95.0kg. †high adiposity was defined as BMI \geq 36.5 kg/m² and low adiposity as BMI <36.5 kg/m²

Table 2: Descriptive data of biochemical characteristics of all study partici	pants (n=401) and subset of normoglycemic
normotensive, normal weight partic	ipants

Variable	n	Mean±SD	Range	Percentile values				
				5 th <i>P</i>	25 th P	50 th <i>P</i>	75 th <i>P</i>	95 th P
All participants								
FSG	397	78.22±7.96	56.00, 124.00	67	73	78	83	92
FSI	396	7.88±7.01	0.100, 59.40	1.1	3.3	6.1	10	21.5
Log insulin*	396	0.743 ± 0.40	-1.027,1.774	0.038	0.521	0.787	1.001	1.333
HOMA-IR	396	1.54±1.38	0.020, 11.73	0.19	0.63	1.15	1.962	4.103
Log HOMA-IR*	396	0.026±0.41	-1.820,1.069	-0.716	-0.201	0.0612	0.293	0.613
Normoglycemic, normotensive,								
normal-weight participants (<i>n</i> =320)								
FSG	320	77.00±6.42	56.0, 91.0	66.95	73	77	81	88
FSI	319	7.34±6.58	0.1, 59.4	1.09	3.1	5.6	9.1	21.5
Log insulin*	319	0.713±0.391	-1.027, 1.774	0.021	0.495	0.752	0.958	1.333
HOMA-IR	319	1.41±1.31	0.02, 11.73	0.189	0.6	1.06	1.73	4.045
Log HOMA-IR*	319	-0.009 ± 0.400	-1.802, 1.069	-0.722	-0.22	0.026	0.239	0.607

FBG, fasting blood glucose in mg/dl; FSI, fasting serum insulin, HOMA-IR, homeostatic model assessment for insulin resistance; log, logarithm to base 10. * the geometric means and percentile values derived from back-transformation of the logarithm of insulin and HOMA-IR yielded values similar to their arithmetic means and percentiles of the untransformed values

of all study participants. The mean \pm SD (95% CI) fasting blood glucose level was 78.22 \pm 7.96 mg/dL (77.44, 79.01), while the median (IQR) fasting insulin was 6.10 (6.70) Miu/L (95% CI: 7.19, 8.57). The

median (IQR) HOMA-IR, the mean, median, and percentile values of FSG, FSI, log FSI, HOMA-IR, and HOMA-IR remained essentially unchanged even after exclusion of women with overweight, hyperglycemia

X1739

Tactors							
	n (%)	Median	IQR	W	Р		
Hyperglycemia*							
Yes	21	1.78	1.9	4929	0.052		
No	375	1.12	1.26				
Weight [†]							
Overweight	27	2.41	1.565	6844.5	< 0.001		
Normal-weight	364	1.1	1.192				
BMI [‡]							
High adiposity	24	1.775	1.798	5312	0.086		
Low adiposity	366	1.12	1.232				
Family history of DM							
No	334	1.15	1.373	9420	0.901		
Yes	57	1.16	1.01				
§Elevated BP							
No	368	1.115	1.255	3177	0.045		
Yes	23	1.56	1.7				
Ethnicity							
Yoruba	247	1.22	1.44	19238.5	0.111		
Others	142	1.09	1.14				
Parity							
Primiparous	181	1.19	1.43	20007	0.248		
Multiparous	207	1.11	1.20				

Table 3: Comparison of HOMA-IR based on categorical

Multiparous2071.111.20n, frequency; IQR, interquartile range; BMI, body-mass index
in kg/m²; DM, diabetes mellitus; BP, blood pressure; W,
Mann-Whitney U value. *hyperglycemia: FBG >91 mg/dL.*Overweight was defined as weight at recruitment \geq 95.0kg and
normal weight as <95.0kg. *High adiposity was defined as BMI
 \geq 36.5 kg/m² and low adiposity as BMI <36.5 kg/m². *Elevated BP:
systolic BP >139 mmHg or diastolic BP >89 mmHg

and hypertension [Table 2]. Also, the back-transformed values of the mean, SD and percentile values of log insulin and log HOMA-IR yielded values almost exactly as the untransformed values.

Correlates and predictors of HOMA-IR

Table 3 shows that women with overweight and elevated blood pressure had significantly higher HOMA-IR compared, respectively, with their normal weight and normotensive counterparts. In contrast, median HOMA-IR levels were similar between groups based on BMI, hyperglycemia and family history of DM.

As shown in Figure 1, HOMA-IR showed a significantly positive but weak linear correlation with BMI [Spearman's rho (ρ) = 0.104, N = 390, P = 0.040] and weight (ρ = 0.102, N = 391, P = 0.043) but not with age (ρ = -0.022, N = 391, P = 0.664) or GA (ρ = 0.043, N = 390, P = 0.397). However, a multivariable linear regression model showed that neither weight or BMI independently predicted HOMA-IR values [standardize beta (95% CI) = 0.017 (-0.050, 0.075, P = 0.875 and standardize beta (95% CI) = 0.042, P = 0.698, respectively)

1740

Table 4 shows that, with variables dichotomized, each of overweight (\geq 95 kg), adiposity (\geq 36.5 kg/m²), hypertension (SBP \geq 140 and/or DBP \geq 90 mmHg), and hyperglycemia (\geq 92 mg/dL) had significant bi-variable association with IR, whereas age, gestational age, parity, and ethnicity had no significant association. In a binary multivariable logistic regression model, overweight, hyperglycemia, and hypertension remained as independent predictors of IR.

DISCUSSION

This report describes the cross-sectional profile of IR, measured with HOMA-IR, in pregnant women in late third trimester and the maternal factors associated with it. Their mean fasting serum glucose level and median insulin were 78.22 ± 7.96 mg/dL and 6.10 (6.70) Miu/L, respectively, while their median (5th, 75th, 95th percentiles) HOMA-IR was 1.15 (0.19, 1.96, 4.10). The prevalence of hyperglycemia (fasting serum glucose ≥91 mg/ dl), and hyperinsulinemia (fasting serum insulin >20.0 μ U/Ml), were 5.3%, and 6.1%, respectively. IR independently associated with overweight, was hyperglycemia, and hypertension-each associated with about 3-fold increased odds of IR; however, the triad jointly explained only 7% of the variance in the IR.

Insulin resistance in pregnancy has been linked to complications like gestational diabetes mellitus, preeclampsia, neonatal macrosomia, preterm births, and increased risk of abdominal delivery.^[18,22] It has also been associated with the risk of developing type II diabetes, obesity, and metabolic and cardiovascular disease later in life.^[17]

HOMA-IR ranges in pregnancy

The HOMA-IR in our sample population ranged widely from 0.02 to 11.73, with median (IQR) of 1.15 (0.63, 1.96). Imoh et al.^[16] reported a similar mean HOMA-IR of 1.3 among mid-trimester pregnant women in Jos (north-central Nigeria), with 23% having IR. The HOMA-IR range observed in our study is also comparable with that documented by Mahjabeen et al.,^[23] Sonogra et al.^[3] and Reyes-Munoz et al.^[24] among women in their third trimester and 0.57-3.97 among Iranian pregnant women as documented by Jahromi and co-workers.^[25] However, a community-based study of nonpregnant Nigerian women in Enugu (Eastern Nigeria) by Young et al.^[15] reported a slightly higher median (IQR) HOMA of 1.45 (0.82-4.06) with about 45% of the women having IR; the higher IR prevalence may be due to the fact that the women were recruited during a free-health screening at a faith-based conference resulting in a clustering effect with higher risk women accessing such opportunity than healthier persons.

$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		Table 4: Categorical bivariate and multivariable determinants of HOMA-IR*							
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	Factors	Insulin r	esistance	Total P^{\dagger} OR		Aor			
HOMA-IR $n (%)$ HOMA-IR $n (%)$ Age		Higher	Lower	-					
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		HOMA-IR	HOMA-IR						
Age < 30 years46 (26.12)130 (73.86)176 (100.00)0.7251.11 (0.70, 1.76)Na >30 years52 (24.19)163 (75.81)215 (100.00)0.7251.11 (0.70, 1.76)NaTotal98 (25.06)293 (74.94)391 (100.00)0.70.90 (0.55, 1.48)Na < 38 weeks67 (24.27)209 (75.72)276 (100.00)0.70.90 (0.55, 1.48)Na $>=38$ weeks30 (26.32)84 (73.68)114 (100.00)1.30 (0.82, 2.06)NaTotal97 (24.87)293 (75.13)390 (100.00)1.30 (0.82, 2.06)NaPrimiparous50 (27.62)131 (72.38)181 (100.00)0.2911.30 (0.82, 2.06)NaMultiparous47 (22.70)160 (77.29)207 (100.00)1.30 (0.82, 2.06)NaMultiparous97 (25.00)291 (75.00)388 (100.00)200 (10.00)3.29 (1.18, 9.1)Weight00.97 (25.00)293 (74.94)391 (100.00)3.31 (1.43, 7.63)1.52 (0.51, 4.5)Normal82 (22.53)282 (77.47)364 (100.00)0.0063.31 (1.43, 7.63)1.52 (0.51, 4.5)Ingh adiposity12 (50.00)12 (50.00)24 (100.00)0.0063.31 (1.43, 7.63)1.52 (0.51, 4.5)Low adiposity85 (23.22)281 (76.78)366 (100.00)2.96 (1.26, 6.95)2.85 (1.18, 6.5)Normal87 (23.64)281 (76.36)368 (100.00)1.30 (0.66, 2.57)NaBPItigh11 (47.83)12 (52.17)23 (100.00)2.96 (1.26, 6		n (%)	n (%)						
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Age								
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	<=30 years	46 (26.12)	130 (73.86)	176 (100.00)	0.725	1.11 (0.70, 1.76)	Na		
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	>30 years	52 (24.19)	163 (75.81)	215 (100.00)					
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Total	98 (25.06)	293 (74.94)	391 (100.00)					
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	GA								
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	<38 weeks	67 (24.27)	209 (75.72)	276 (100.00)	0.7	0.90 (0.55, 1.48)	Na		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	>=38 weeks	30 (26.32)	84 (73.68)	114 (100.00)					
$\begin{array}{l lllllllllllllllllllllllllllllllllll$	Total	97 (24.87)	293 (75.13)	390 (100.00)					
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Parity								
Multiparous47 (22.70)160 (77.29)207 (100.00)Total97 (25.00)291 (75.00)388 (100.00)Weight 0 0 0 0 0 Overweight16 (59.26)11 (40.74)27 (100.00) < 0.001 5.00 (2.23, 11.20) 3.29 (1.18, 9.1Normal82 (22.53)282 (77.47) 364 (100.00) 0 0 0 0 0 Total98 (25.06)293 (74.94)391 (100.00) 0.006 3.31 (1.43, 7.63) 1.52 (0.51, 4.5Low adiposity12 (50.00)12 (50.00)24 (100.00) 0.006 3.31 (1.43, 7.63) 1.52 (0.51, 4.5Low adiposity85 (23.22)281 (76.78) 366 (100.00) 0.006 3.31 (1.43, 7.63) 1.52 (0.51, 4.5Low adiposity85 (23.22)281 (76.78) 366 (100.00) 0.006 3.31 (1.43, 7.63) 1.52 (0.51, 4.5Normal97 (23.87)293 (75.23)390 (100.00) 0.006 3.31 (1.43, 7.63) 1.52 (0.51, 4.5BP 0 0.006 0.006 0.006 0.006 0.006 0.006 BP 0 0.006 0.006 0.006 0.006 0.006 0.006 Family hx of DM 0 0.006 0.006 0.006 0.006 0.006 0.006 Family hx of DM 0 0.006 0.006 0.006 0.006 0.006 0.006 0.006 For all98 (25.06)293 (74.94) 0.000 0.006 0.006 0.006 $0.$	Primiparous	50 (27.62)	131 (72.38)	181 (100.00)	0.291	1.30 (0.82, 2.06)	Na		
Total97 (25.00)291 (75.00) $388 (100.00)$ Weight0verweight16 (59.26)11 (40.74)27 (100.00)< 0.001	Multiparous	47 (22.70)	160 (77.29)	207 (100.00)					
WeightImage: Constraint of the constrain	Total	97 (25.00)	291 (75.00)	388 (100.00)					
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Weight								
Normal 82 (22.53) 282 (77.47) 364 (100.00) Total 98 (25.06) 293 (74.94) 391 (100.00) BMI	Overweight	16 (59.26)	11 (40.74)	27 (100.00)	< 0.001	5.00 (2.23, 11.20)	3.29 (1.18, 9.13)		
Total 98 (25.06) 293 (74.94) 391 (100.00) BMI High adiposity 12 (50.00) 12 (50.00) 24 (100.00) 0.006 3.31 (1.43, 7.63) 1.52 (0.51, 4.5) Low adiposity 85 (23.22) 281 (76.78) 366 (100.00) 390 (100.00) Total 97 (23.87) 293 (75.23) 390 (100.00) 2.96 (1.26, 6.95) 2.85 (1.18, 6.9) BP High 11 (47.83) 12 (52.17) 23 (100.00) 2.96 (1.26, 6.95) 2.85 (1.18, 6.9) Normal 87 (23.64) 281 (76.36) 368 (100.00) 391 (100.00) 1.30 (0.66, 2.57) Na Family hx of DM No 86 (25.75) 248 (74.25) 334 (100.00) 1.30 (0.66, 2.57) Na Yes 12 (21.05) 45 (78.95) 57 (100.00) 1.30 (0.66, 2.57) Na Ethnicity Ethnicity 593 (74.94) 391 (100.00) 593 (74.94) 591 (100.00)	Normal	82 (22.53)	282 (77.47)	364 (100.00)			,		
BMI High adiposity 12 (50.00) 12 (50.00) 24 (100.00) 0.006 3.31 (1.43, 7.63) 1.52 (0.51, 4.5) Low adiposity 85 (23.22) 281 (76.78) 366 (100.00) 390 (100.00) 100.000 Total 97 (23.87) 293 (75.23) 390 (100.00) 2.96 (1.26, 6.95) 2.85 (1.18, 6.9) BP High 11 (47.83) 12 (52.17) 23 (100.00) 2.96 (1.26, 6.95) 2.85 (1.18, 6.9) Normal 87 (23.64) 281 (76.36) 368 (100.00) 391 (100.00) 1.30 (0.66, 2.57) Na Family hx of DM No 86 (25.75) 248 (74.25) 334 (100.00) 1.30 (0.66, 2.57) Na Yes 12 (21.05) 45 (78.95) 57 (100.00) 1.30 (0.66, 2.57) Na Total 98 (25.06) 293 (74.94) 391 (100.00) 1.30 (0.66, 2.57) Na Yes 12 (21.05) 45 (78.95) 57 (100.00) 1.30 (0.66, 2.57) Na Ethnicity 593 (74.94) 391 (100.00) 593 (74.94) 591 (100.00) 593 (74.94)	Total	98 (25.06)	293 (74.94)	391 (100.00)					
High adiposity 12 (50.00) 12 (50.00) 24 (100.00) 0.006 3.31 (1.43, 7.63) 1.52 (0.51, 4.5) Low adiposity 85 (23.22) 281 (76.78) 366 (100.00) 366 (100.00) 366 (100.00) Total 97 (23.87) 293 (75.23) 390 (100.00) 2.96 (1.26, 6.95) 2.85 (1.18, 6.9) BP High 11 (47.83) 12 (52.17) 23 (100.00) 2.96 (1.26, 6.95) 2.85 (1.18, 6.9) Normal 87 (23.64) 281 (76.36) 368 (100.00) 391 (100.00) 391 (100.00) Family hx of DM No 86 (25.75) 248 (74.25) 334 (100.00) 1.30 (0.66, 2.57) Na Yes 12 (21.05) 45 (78.95) 57 (100.00) 1.30 (0.66, 2.57) Na Ethnicity Ethnicity 391 (100.00) 391 (100.00) 391 (100.00) 391 (100.00)	BMI								
Low adiposity 85 (23.22) 281 (76.78) 366 (100.00) Total 97 (23.87) 293 (75.23) 390 (100.00) BP High 11 (47.83) 12 (52.17) 23 (100.00) 2.96 (1.26, 6.95) 2.85 (1.18, 6.95) Normal 87 (23.64) 281 (76.36) 368 (100.00) Total 98 (25.06) 293 (74.94) 391 (100.00) Family hx of DM No 86 (25.75) 248 (74.25) 334 (100.00) 1.30 (0.66, 2.57) Na Yes 12 (21.05) 45 (78.95) 57 (100.00) Total 98 (25.06) 293 (74.94) 391 (100.00) Ethnicity	High adiposity	12 (50.00)	12 (50.00)	24 (100.00)	0.006	3.31 (1.43, 7.63)	1.52 (0.51, 4.50)		
Total 97 (23.87) 293 (75.23) 390 (100.00) BP High 11 (47.83) 12 (52.17) 23 (100.00) 2.96 (1.26, 6.95) 2.85 (1.18, 6.95) Normal 87 (23.64) 281 (76.36) 368 (100.00) 391 (100.00) Total 98 (25.06) 293 (74.94) 391 (100.00) 1.30 (0.66, 2.57) Na Yes 12 (21.05) 45 (78.95) 57 (100.00) 1.30 (0.66, 2.57) Na Ethnicity Ethnicity 100.000 1.30 (0.66, 2.57) Na	Low adiposity	85 (23.22)	281 (76.78)	366 (100.00)					
BP High 11 (47.83) 12 (52.17) 23 (100.00) 2.96 (1.26, 6.95) 2.85 (1.18, 6.95) Normal 87 (23.64) 281 (76.36) 368 (100.00) Total 98 (25.06) 293 (74.94) 391 (100.00) Family hx of DM No 86 (25.75) 248 (74.25) 334 (100.00) Yes 12 (21.05) 45 (78.95) 57 (100.00) Total 98 (25.06) 293 (74.94) 391 (100.00) Ethnicity Ethnicity 391 (100.00)	Total	97 (23.87)	293 (75.23)	390 (100.00)					
High 11 (47.83) 12 (52.17) 23 (100.00) 2.96 (1.26, 6.95) 2.85 (1.18, 6.95) Normal 87 (23.64) 281 (76.36) 368 (100.00) 368 (100.00) 368 (100.00) Total 98 (25.06) 293 (74.94) 391 (100.00) 391 (100.00) 1.30 (0.66, 2.57) Na Family hx of DM Ves 12 (21.05) 45 (78.95) 57 (100.00) 1.30 (0.66, 2.57) Na Yes 12 (21.05) 45 (78.95) 57 (100.00) 1.30 (0.66, 2.57) Na Ethnicity 593 (74.94) 391 (100.00) 1.30 (0.66, 2.57) Na	BP								
Normal 87 (23.64) 281 (76.36) 368 (100.00) Total 98 (25.06) 293 (74.94) 391 (100.00) Family hx of DM V V V No 86 (25.75) 248 (74.25) 334 (100.00) 1.30 (0.66, 2.57) Na Yes 12 (21.05) 45 (78.95) 57 (100.00) 1.30 (0.66, 2.57) Na Ethnicity V V V V V V V	High	11 (47.83)	12 (52.17)	23 (100.00)		2.96 (1.26, 6.95)	2.85 (1.18, 6.90)		
Total 98 (25.06) 293 (74.94) 391 (100.00) Family hx of DM	Normal	87 (23.64)	281 (76.36)	368 (100.00)			(, , , , , , , , , , , , , , , , , , ,		
Family hx of DM No 86 (25.75) 248 (74.25) 334 (100.00) 1.30 (0.66, 2.57) Na Yes 12 (21.05) 45 (78.95) 57 (100.00) Total 98 (25.06) 293 (74.94) 391 (100.00) Ethnicity	Total	98 (25.06)	293 (74.94)	391 (100.00)					
No 86 (25.75) 248 (74.25) 334 (100.00) 1.30 (0.66, 2.57) Na Yes 12 (21.05) 45 (78.95) 57 (100.00) 1.30 (0.66, 2.57) Na Total 98 (25.06) 293 (74.94) 391 (100.00) Ethnicity	Family hx of DM								
Yes 12 (21.05) 45 (78.95) 57 (100.00) Total 98 (25.06) 293 (74.94) 391 (100.00) Ethnicity	No	86 (25.75)	248 (74.25)	334 (100.00)		1.30 (0.66, 2.57)	Na		
Total 98 (25.06) 293 (74.94) 391 (100.00) Ethnicity 200 (74.94) 200 (74.94) 200 (74.94)	Yes	12(21.05)	45 (78 95)	57 (100.00)		1.50 (0.00, 2.07)			
Ethnicity	Total	98 (25.06)	293 (74 94)	391 (100.00)					
	Ethnicity	>0 (20.00)		591 (100.00)					
Yoruba 70 (28 34) 177 (71 66) 247 1 61 (0.98 2.65) NA	Yoruba	70 (28 34)	177 (71.66)	247		1 61 (0 98 2 65)	NA		
Others $28(1972)$ $114(8028)$ 142	Others	28 (19 72)	114 (80 28)	142		1.01 (0.90, 2.00)	1111		
Total $98(2519)$ $291(7481)$ 389	Total	98 (25 19)	291 (74.81)	389					
Hyperglycemia	Hyperglycemia)0 (20.17)	271 (71.01)	507					
High $10(47.62)$ $11(52.38)$ $21(100.00)$ 0.021 $2.88(1.18.7.00)$ $2.08(1.10.60)$	High	10 (47 62)	11 (52 38)	21 (100.00)	0.021	2 88 (1 18 7 00)	2 98 (1 10 6 90)		
Normal $90(24.00)$ $285(76.00)$ $375(100.00)$ 0.021 $2.00(1.10, 7.00)$ $2.90(1.17, 0.5)$	Normal	90(24.00)	285 (76.00)	375(100.00)	0.021	2.00 (1.10, 7.00)	2.76 (1.17, 0.90)		

OR, crude odds ratio from a 2 x 2 contingency tables; aOR, adjusted odds ratios from a binary logistic multivariable regression model conducted with HOMA-IR as dependent variables and weight, BMI, hypertension and hyperglycemia as independent variables; na, not applicable- not included in logistic regression because of bivariate non-significance. R^2 for the multivariable logistic regression model explained 6.9 of the variance in the outcome variable; R^2 for overweight increased to 4.7 (95% CI: 2.1, 10.6) when BMI was deleted. There was no significant multi-collinearity among the variables (highest variable inflation factor was 1.5). P value from Fisher's exact test

Risk factors for IR

Interestingly, the mean, median, and percentiles of fasting blood glucose (FBG), fasting serum insulin (FSI), and HOMA-IR for our cohort remained essentially same after we excluded those with hyperglycemia, elevated BP, and overweight. This was further corroborated by our observation that variables like weight and BMI had weak, largely nonlinear influence on our sample's HOMA-IR levels. Our observation of overweight as an independent risk factor for IR agrees with similar finding by Imoh *et al.*^[26] in north-central Nigeria. Although overweight, hypertension and hyperglycemia were independently associated with the presence of IR in a multivariable logistic regression, their overall contribution to IR was as they jointly explained only about 7% of its variance. Thus, we hypothesize that other factors, especially the pregnancy state itself known to be a state of IR, may account for the remaining variance.

HOMA-IR and GDM

The women in our cohort who had hyperglycemia may be regarded as having GDM because they satisfied one of its diagnostic criteria-fasting serum glucose between 92 and 125 mg/dL (World Health Organisation, 2013).^[16] According to Olumodeji et al.,[27] this single criterion is almost 100% sensitive to detect pregnant Nigerian women with GDM. Hence, we may consider that the prevalence of GDM in our cohort was 5.3%, which is similar to 7.7% reported by Olumodeji and colleagues among Nigerian pregnant women accessing ANC at 24-32 weeks in south-west Nigeria.^[27] In our study, the median HOMA-IR was similar between the subsets of participants with hyperglycemia and normoglycemia, in contrast to finding by Mohammed et al.^[28] who noted that pregnant women with GDM had significantly higher HOMA-IR than those without GDM in northern Nigeria, and Wang et al.[10] who reported similar observation among Chinese mothers. Our observation of nondifference between the HOMA-IR of the GDM and normoglycemic groups may be because we used only FSG to identify those with hyperglycemia, possibly missing others who could have been identified with the other criterion for the diagnosis of GDM:(World Health Organisation, 2013)^[18] 2-h postprandial glucose. In contrast to the finding by Imoh et al.^[16] a family history of DM was not independently associated with IR in our study.

HOMA-IR and adiposity

In a strikingly similar agreement with an earlier study by Imoh and Ocheke^[17] in north-central Nigeria, we found overweight, based on absolute weight of pregnant women (\geq 95 kg) rather than their BMI, to be associated with a three-fold increased odds of IR. Our finding also suggests that, in pregnant women, weight is a better determinant of IR than BMI. It may be interesting thus to determine if weight is a better measure of adiposity than BMI. Of the triad of factors associated with IR in our cohort, while overweight may be regarded as a predisposing or potentiating factor for IR, hypertension and hyperglycemia may be regarded as complications or outcomes of the physio-pathological processes underlying IR.^[30,31] Thus, the prevention or amelioration of pre-pregnancy overweight or excessive weight gain during pregnancy is a potential target for the prevention of IR and its maternal consequences (including hyperglycemia and hypertension) and subsequent peri-neonatal complications.^[31] Higher maternal physical activity, especially pre-pregnancy, is associated with lower risk of pregnancy-associated IR.^[22]

HOMA-IR and gestational age

1742

We had expected that HOMA-IR would correlate positively with GA because hyperinsulinemia and

HOMA-IR generally tend to increase with increasing gestational age. However, HOMA-IR was not associated with GA in our cohort, perhaps because we studied a relatively narrow range of GA. Nonetheless, while some authors reported increasing IR with increasing GA, others did not. For example, while Sonagra et al.^[3] reported that pregnant women at second and third trimester had serum insulin levels that were 29% and 61% higher than levels of age-matched nonpregnant counterparts, Jahromi et al.[25] found no association or correlation between IR and gestational age in Iranian third-trimester pregnant women, presumably due to small sample size or ethnic variations in other risk factors. Similarly, Sonagra et al.[3] in their study did not observe any relationship between age and incidence of IR in all the trimesters.

Limitations

Unlike previous studies on HOMA-IR in pregnancy, we did not compare the clinical and biochemical characteristics of our cohort, including their HOMA-IR, with nonpregnant healthy controls thus limiting a better evaluation of the effect of pregnancy on IR. However, we explored the possible association between HOMA-IR and GDM and hypertension, despite the small proportion of these subsets. The absence of pre-pregnancy weight limits our ability to delineate if the association between overweight and IR was as a result of excess pre-pregnancy weight or excess intra-pregnancy weight gain or both; nonetheless, we confirmed a previous observation that absolute weight, even in late trimester, is a useful alternative measure of adiposity in the absence of pre-pregnancy weight.

Suggestions for further studies

There is need for larger population studies, preferably multi-centric, comparing the clinical and biochemical characteristics and HOMA-IR in healthy pregnant and nonpregnant women, as well as prospectively investigate effect of maternal IR on perinatal, neonatal and long-term maternal outcomes.

CONCLUSION

In this cross-sectional report of predictors of IR among nondiabetic Nigerian pregnant women in late third trimester, IR was independently associated with overweight, elevated blood pressure, and hyperglycemia. Thus, control of adiposity may be a potential target for the control of IR and, consequently, its potential outcomes.

Authorship criteria/contribution

I hereby declare that Joy Chionuma and Ibironke Akinola play a major role in the concept and design

of the study. We were all involved in literature search and conduct of the study. Samples were analyzed by Dr Dada. Dr Chionuma and Dr Ubuane played a larger role in data analysis and interpretation. They also supervised the manuscript writing. Editing and review of manuscript was by all authors supervised by Dr. Chionuma. We all agreed on the final version of the manuscript for submission.

Acknowledgement

This work was funded by the Research & Grants Management Office of the Lagos State University College of Medicine (LASUCOM), Ikeja, Lagos, Nigeria. The funder had no role in the design, conduct, data acquisition and decision to publish the findings.

Part of this data was presented as a conference abstract at the 7th Biennial Faculty day and Scientific Conference, College of Medicine, Lagos State University in December, 2021.

Financial support and sponsorship

This work was supported by the Research and Grant Management office of the Lagos State University College of Medicine, Ikeja.

Conflicts of interest

There are no conflicts of interest.

References

- 1. American Diabetes Association (ADA) Classification and diagnosis of diabetes. Diabetes Care 2017;40:S11-24.
- 2. Catalano PM. Obesity. Insulin resistance and pregnancy outcome. Reproduction 2010;140:365-71.
- Sonagra AD, Biradar SM, K D, Murthy D S J. Normal pregnancy- a state of insulin resistance. J Clin Diagn Res 2014;8:CC01-3.
- Sun YY, Juan J, Xu QQ, Su RN, Hirst JE, Yang HX. Increasing insulin resistance predicts adverse pregnancy outcomes in women with gestational diabetes mellitus. J Diabetes 2020;12:438-46.
- Ryan EA, Enns L. Role of gestational hormones in the induction of insulin resistance (IR). J Clin Endocrinol Metab1988;67:341-7.
- Zhao X, Li N, Jia R, Chen, Wang L. The factors affecting the physical development of neonates in pregnant women with or without gestational diabetes mellitus. PloS One 2021;16:e0251024. doi: 10.1371/journal.pone. 0251024.
- Benhalima K, Van Crombrugge P, Moyson C, Verhaeghe J, Vandeginste S, Verlaenen H, *et al.* Characteristics and pregnancy outcomes across gestational diabetes mellitus subtypes based on insulin resistance. Diabetologia 2019;62:2118-28.
- Lin J, Jin H, Chen L. Associations between insulin resistance and adverse pregnancy outcomes in women with gestational diabetes mellitus: A retrospective study. BMC Pregnancy Childbirth 2021;21:526.
- Akinola IJ, Oyenusi EE, Odusote OA, Oduwole A, Njokanma OF. Insulin resistance profile of apparently healthy term neonates in Lagos, Nigeria. J Clin Neonatol 2018;7:71-4.
- 10. Wang Q, Huang R, Yu B, Cao F, Wang H, Zhang M, *et al.* Higher fetal insulin resistance in Chinese pregnant women with gestational diabetes mellitus and correlation with maternal insulin

resistance. PLoS One 2013;8:e59845. doi: 10.1371/journal.pone. 0059845.

- Lowe WL, Lowe LP, Kuang A, Catalano PM, Nodzenski M, Talbot O, *et al.* Maternal glucose levels during pregnancy and childhood adiposity in the hyperglycemia and adverse pregnancy outcome follow-up study. Diabetologia 2019;62:598-610.
- Tanaka K, Yamada K, Matsushima M, Izawa T, Furukawa S, Kobayashi Y, *et al.* Increased maternal insulin resistance promotes placental growth and decreases placental efficiency in pregnancies with obesity and gestational diabetes mellitus. J Obstet Gynaecol Res 2018;44:74-80.
- Tabrang H, Jusuf EC, Sanusi HE. Insulin resistance (IR) in pregnant women at the Mother and Child Hospital Khadijah, Makassar, Indonesia. Enfermeria Clinica. 2020;30(Suppl 2):84-7. doi: https://doi.org/10.1016/j.enfcli.2019.07.038.
- Cohen O, Epstein GS, Weisz B, Homko CJ, Sivan E. Longitudinal assessment of insulin sensitivity in pregnancy. Validation of the homeostatic model assessment. Clin Endocrinol 2006;64:640-4.
- Young EE, Okafor CN, Iroezindu MO, Agbalu IS. Insulin resistance, metabolic syndrome, and lipids in African women. Niger J Clin Pract 2016;19:793-8.
- Imoh LC, Inaku KO, Abu B, Amadu NO. Lipid profile and insulin resistance in pregnant women with family history of diabetes mellitus. Jos Journal of Medicine 2014;8:19-22.
- Imoh LC, Ocheke, A. Correlation between maternal weight and insulin resistance in second half of pregnancy. Niger Med J 2014;55:465-8.
- World Health Organisation. Diagnostic Criteria and Classification of Hyperglycaemia First Detected in Pregnancy. Geneva: World Health Organisation; 2013. Available from: https://apps.who.int/ iris/handle/10665/85975. [Last accessed on 2021 Dec 30].
- Masoodian SM, Omidifar A, Moradkhani S, Asiabonha M, Khoshmirsafa M. HOMA-IR mean values in healthy individuals: A population based study in Iranian subjects (pre-print). Research Square 2021;1-12. doi: 10.21203/rs. 3.rs-816508/v1.
- Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003;26:3320-5.
- Cai C, Zhang Z, Mc Donald S, Strom C, Skow RJ, May LE, et al. Leisure-time physical activity before and during pregnancy is associated with improved insulin resistance in late pregnancy. Int J Environ Res Public Health 2021;18:4413. doi: 10.3390/ ijerph 18094413.
- Adeva-Andany MM, Martínez-Rodríguez J, González-Lucán M, Fernández-Fernández C, Castro-Quintela E. Insulin resistance is a cardiovascular risk factor in humans. Diabetes Metab Syndr 2019;13:1449-55.
- Mahjabeen S, Rahman AKM, Hossain M, Mustari M, Abedin M, Mahmood T, *et al.* Insulin sensitivity and insulin secretion estimated by homeostatic model assessment (HOMA) in gestational diabetes mellitus. J Biosci Med 2020;8:44-54.doi: 10.4236/jbm. 2020.87005.
- Reyes-Munoz E, Martinez-Herrera EM, Ortega-Gonzalez C, Arce-Sanchez L, Avila-Carrasco A, Zamora-Escudero R. HOMA-IR and Quicki reference values in pregnancy in Mexican women. Ginecol Obstet Mex 2017;85:306-13.
- Jahromi AS, Zareian P, Madani A. Insulin resistance and interleukin-1ß during normal pregnancy. Asian J Biochem 2011;6:366-72.
- Imoh LC, Ogunkeye OO, Isichei CO, Gadzama AA, John C, Ocheke AN. Severe maternal insulin resistance in pregnancy: An independent predictor of fetal macrosomia J Med Trop 2016;18:73-8.

- Olumodeji AM, Okere RA, Adebara I, Ajani O, Adiwara OE, Ghazali SM, *et al.* Implementing the 2013 who diagnostic criteria for gestational diabetes mellitus in a rural Nigerian population. Pan Afr Med J 2020;36:1-8. doi: 10.11604/pamj. 2020.36.208.20818.
- Mohammed A, Aliyu IS, Manu M. Correlation between circulating level of tumor necrosis factor-alpha and insulin resistance in Nigerian women with gestational diabetes mellitus. Ann Afr Med 2018;17:168-71.
- 29. Abhari FR, Andorieh MG, Farokhar A, Ahmady S. Estimating rate of insulin resistance in patients with preeclampsia using Homa-IR index and comparison with

non-preeclampsia pregnant women. BioMed Res Int 2014. doi: 10.1155/2014/140851.

- Forbes S, Barr SM, Reynolds RM, Semple S, Gray C, Andrew R, et al. Convergence in insulin resistance between very severely obese and lean women at the end of pregnancy. Diabetologia 2015;58:2615-26.
- Elochukwu AC, Usoro CO, Nsonwu AC, Offor SJ, Orji OC. Evaluation of tumor necrosis factor alpha, insulin, and homeostasis model assessment of insulin resistance among obese participants living in Calabar, Nigeria. Trop J Med Res 2017;20:45. doi: 10.4103/1119-0388.198120.

